{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:26:18Z","timestamp":1783052778060,"version":"3.54.6"},"reference-count":55,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Psychedelics are an increasingly active area of research and pharmaceutical development. This includes abuse potential assessment to better understand their pharmacological mechanisms and effects and guide controlled substance regulation. Psychedelics pose challenges to abuse assessments to ensure valid, reliable, and generalizable outcomes and safe study conduct.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>Key nonclinical techniques, for example, receptor binding and functional assays in vitro, and nonclinical physical dependence determinations, are easily adaptable to psychedelics. However, the entactogens (weak reinforcers) and hallucinogens (non-reinforcers) require more flexible approaches than typically recommended by regulatory agencies. Phase 1 pharmacokinetic\/pharmacodynamic safety studies and Phases 2\/3 efficacy\/safety trials with systematic monitoring of abuse-related adverse events are readily applicable to psychedelics. Human abuse trials require modification because supratherapeutic doses may not be safe and procedures, for example, personal monitors to manage serious adverse events, might bias outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recommendations:<\/jats:title>\n                    <jats:p>Abuse-related studies for psychedelics requiring approval by Food and Drug Administration and other agencies should take into consideration existing knowledge that will vary from extensive, for example, psilocybin, to zero for novel hallucinogens and entactogens. Many abuse assessments can be reasonably applied to animals and humans without compromising scientific integrity. Modification of existing techniques and incorporating a broader range of nonclinical tests should ensure generalizable outcomes. Human abuse studies merit reconsideration and possible modification to ensure safety and validity for psychedelic drug evaluation. Other nonclinical and clinical methods can provide evaluations of the pharmacological equivalence of test drugs to known drugs of abuse to provide context to the abuse assessment and guide drug scheduling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811221140004","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T02:25:41Z","timestamp":1672626341000},"page":"33-44","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective"],"prefix":"10.1177","volume":"37","author":[{"given":"Jack E.","family":"Henningfield","sequence":"first","affiliation":[{"name":"PinneyAssociates, Inc, Bethesda, MD, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Ashworth","sequence":"additional","affiliation":[{"name":"PinneyAssociates, Inc, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-9632","authenticated-orcid":false,"given":"David J.","family":"Heal","sequence":"additional","affiliation":[{"name":"DevelRx Ltd, BioCity, Nottingham, UK"},{"name":"Department of Pharmacy and Pharmacology, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-8475","authenticated-orcid":false,"given":"Sharon L.","family":"Smith","sequence":"additional","affiliation":[{"name":"DevelRx Ltd, BioCity, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,1]]},"reference":[{"key":"bibr1-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00099-1"},{"key":"bibr2-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e328363d1a4"},{"key":"bibr3-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_178"},{"key":"bibr4-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.02.018"},{"key":"bibr5-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4777-4"},{"key":"bibr6-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.03.006"},{"key":"bibr7-02698811221140004","author":"Calderon SN","year":"2022","journal-title":"Neuropharmacol"},{"key":"bibr8-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-420172-9.00010-2"},{"key":"bibr9-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.11.028"},{"key":"bibr10-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05533-9"},{"key":"bibr11-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.04.003"},{"key":"bibr12-02698811221140004","volume-title":"American College of Neuropsychopharmacology 60th Annual Meeting","author":"Coker A","year":"2021"},{"key":"bibr13-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401509"},{"key":"bibr14-02698811221140004","unstructured":"European Medicines Agency (2000) ICH S7A safety pharmacology studies for human pharmaceuticals. Available at https:\/\/www.ema.europa.eu\/en\/ich-s7a-safety-pharmacology-studies-human-pharmaceuticals (accessed 31 December 2021)."},{"key":"bibr15-02698811221140004","unstructured":"European Medicines Agency (2006) Guidance of the non-clinical investigation of the dependence potential of medicinal products. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003360.pdf (accessed 31 December 2021)."},{"key":"bibr16-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.07.018"},{"key":"bibr17-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200403000-00007"},{"key":"bibr18-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2018.11.002"},{"key":"bibr19-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2016.08.001"},{"key":"bibr20-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1177\/2050324520974486"},{"key":"bibr21-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00098-X"},{"key":"bibr22-02698811221140004","first-page":"1","volume-title":"Advances in Substance Abuse","author":"Griffiths RR","year":"1980"},{"key":"bibr23-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0457-5"},{"key":"bibr24-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108094300"},{"key":"bibr25-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2014.07.016"},{"key":"bibr26-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107933"},{"key":"bibr27-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.049"},{"key":"bibr28-02698811221140004","unstructured":"Heal DJ, Kulkarni RS, Pinder L, et al. (2018c) Dasotraline is a monoamine reuptake inhibitor not a releasing agent as revealed by tetrodotoxin (TTX) sensitivity in microdialysis in the nucleus accumbens of freely-moving rats. Presented at the 80th annual meeting of college on problems of drug dependence, Washington, DC June 9\u201314. Available at https:\/\/d2p55c5k0gw6a2.cloudfront.net\/wp-content\/uploads\/2018\/10\/abstracts_2018_for_app_update_101918.pdf#page=444"},{"key":"bibr29-02698811221140004","first-page":"56","volume-title":"Central Serotonin Receptors and Psychotropic Drugs","author":"Heal DJ","year":"1992"},{"key":"bibr30-02698811221140004","unstructured":"Heal DJ, Smith SL, Gosden J, et al. (2018b) An investigation of the discriminative stimulus and reinforcing effects of cannabidiol in rats. Presented at The society for neurosciences neuroscience meeting, Washington, DC November 3\u20137. Available at https:\/\/www.abstractsonline.com\/pp8\/#!\/4649\/presentation\/25834"},{"key":"bibr31-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109220"},{"key":"bibr32-02698811221140004","volume-title":"LSD: My Problem Child and Insights\/Outlooks","author":"Hofmann A","year":"2013"},{"key":"bibr33-02698811221140004","volume-title":"Report of the International Narcotics Control Board for 1994","author":"International Narcotics Control Board","year":"1994"},{"key":"bibr34-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2019.106602"},{"key":"bibr35-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.012"},{"key":"bibr36-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"bibr37-02698811221140004","unstructured":"National Academies of Sciences (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. https:\/\/nap.nationalacademies.org\/catalog\/24625\/the-health-effects-of-cannabis-and-cannabinoids-the-current-state (accessed December 2021)."},{"key":"bibr38-02698811221140004","unstructured":"National Institute on Drug Abuse (2021) Hallucinogens drug facts. Available at: https:\/\/nida.nih.gov\/publications\/drugfacts\/hallucinogens (accessed 31 December 2021)."},{"key":"bibr39-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1124\/pr.112.007419"},{"key":"bibr40-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2003.11.002"},{"key":"bibr41-02698811221140004","volume-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","author":"O\u2019brien CP","year":"2015"},{"key":"bibr42-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1124\/pr.112.007138"},{"key":"bibr43-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000253"},{"key":"bibr44-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000516"},{"key":"bibr45-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.776"},{"key":"bibr46-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.11.029"},{"key":"bibr47-02698811221140004","unstructured":"Smith SL, Burnett M, Hallam M, et al. (2018) Which drug is the most reinforcing? Comparison of heroin, cocaine, MDMA, and nicotine by intravenous self-administration. British Pharmacol Soc Abstract 176: 3065\u20133066. Available at https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/epdf\/10.1111\/bph.14681"},{"key":"bibr48-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118822111"},{"issue":"3","key":"bibr49-02698811221140004","doi-asserted-by":"crossref","DOI":"10.1016\/S0376-8716(03)00096-6","volume":"70","author":"Spillane J","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"bibr50-02698811221140004","author":"Synan C","year":"2018","journal-title":"59th annual American College of Neuropsychopharmacology (ACNP) virtual meeting"},{"key":"bibr51-02698811221140004","unstructured":"U.S. Food and Drug Administration (2017) Assessment of abuse potential of drugs: Guidance for industry. US Department of Health and Human Services. Available at https:\/\/www.fda.gov\/media\/116739\/download (accessed 31 December 2021)."},{"key":"bibr52-02698811221140004","unstructured":"U.S. Food and Drug Administration (2020) CDER breakthrough therapy designation approvals. Corrected data for December 31, 2020. Available at: https:\/\/www.fda.gov\/media\/95302\/download (accessed 31 December 2020)."},{"key":"bibr53-02698811221140004","doi-asserted-by":"publisher","DOI":"10.1007\/BF00169306"},{"key":"bibr54-02698811221140004","unstructured":"Winstock AR, Timmerman C, Davies E, et al. (2021) Global Drug Survey (GDS) 2020 psychedlics key findings report. Available at: https:\/\/www.globaldrugsurvey.com\/gds-2020-psychedelics-report\/ (accessed December 2021)."},{"key":"bibr55-02698811221140004","unstructured":"Yakowicz W (2021) The future of psychedelic medicine might skip the trip. Forbes. Available at: https:\/\/www.forbes.com\/sites\/willyakowicz\/2021\/06\/23\/the-future-of-psychedelic-medicine-might-skip-the-trip-rick-doblin-bryan-roth-mindmed-darpa-maps\/?sh=61ce2828244f (accessed December 2021)."}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811221140004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811221140004","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811221140004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:13Z","timestamp":1777507873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811221140004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/02698811221140004"],"URL":"https:\/\/doi.org\/10.1177\/02698811221140004","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}